TwentyTwentyTweets
- Sorry to have missed you! Would love to know what difference your approach has made to QoL for someone with… twitter.com/i/web/status/1… 6 hours ago
- And again - think before you click - and then buy locally instead. #BeKind Delivery disaster: the hidden environmen… twitter.com/i/web/status/1… 1 week ago
- How about we all return to forward planning, buying local and/or direct from supplier? #BeKind Concerns over safety… twitter.com/i/web/status/1… 1 week ago
-
Recent Posts
Pages
Tag Archives: National Institute for Health and Care Excellence
Medical advisory body “NICE” should not spend too much time valuing drugs.
The UK National Institute for Health and Care Excellence (“NICE”) is currently holding a public consultation over its proposals for evaluating drugs. Drugs that are approved by NICE automatically become available for doctors to prescribe under the NHS throughout England … Continue reading
Posted in Business, CCGs, Commissioning, Department of Health, Drugs, Elderly, equality, Genetics, GPs, Health and Wellbeing, Health Bill, Health reform, Inequality, Innovation, Jeremy Hunt, NHS, NHS reforms, Patients, Pharma, Policy, Public Health, Research, Technology, Uncategorized, Wellbeing
Tagged 2020health, Clinical Commissioning Group, Commissioning, Department of Health, dose, elderly, General practitioner, government, GP, GPs, health, Health Bill, innovation, Jeremy Hunt, medicine, Medicines and Healthcare products Regulatory Agency, MHRA, National Health Service, National Institute for Health and Care Excellence, NHS, NICE, Old age, patient, Patients, pharmaceutical, PPRS, pricing, Proportionate QALY, Public Health, QALY, R&D, Research, value-based, value-based pricing
Leave a comment
